- Abbott Q2 led by strong device, diagnostic sales as it boosts profit forecastAbbott turned in a stronger-than-expected second quarter, allaying market concerns that subsidy cuts to the Affordable Care Act by the Trump administration would hurt medtech firms.Fierce Biotech · 10d ago↗ source
- GSK axes key cough drug candidate after phase 3 data end blockbuster hopesGSK has ended development of camlipixant in chronic cough after delivering mixed phase 3 data, dealing a major blow to a potential blockbuster that analysts saw as the key 2026 catalyst for the dru…Fierce Biotech · 10d ago↗ source
- Dimerix snaps up Mission’s stalled, phase 2-ready kidney disease candidate in $292M dealDimerix has bought an acute kidney injury drug from Mission Therapeutics, paying $5 million upfront and committing up to $287 million in milestones for the phase 2-ready asset.